Neurological Drug Loaded Glyconanoparticle Formulation Service
Overview
Glyconanoparticle offers several advantages in delivering drugs, including good biocompatibility, biodegradability, stability, targeted accumulation, increased penetration through the blood-brain barrier, and reduced side effects. It aids drug absorption by targeting specific sites in brain cells. CD BioGlyco focuses on the pharmaceutical sector and provides a one-stop neurological drug-loaded glyconanoparticle formulation service for Alzheimer's disease and Parkinson's disease (PD) based on our GlycoNano™ Platform. We have extensive hands-on experience and the ability to customize glyconanoparticles by developing high-quality nano-delivery systems to facilitate improved drug delivery efficiency, bioavailability, and therapeutic efficacy in preclinical models.
Integrated and Innovative Neurological Drug-loaded Glyconanoparticle Formulation Service
With expertise and experience in glyconanoparticle development, our laboratory staff provides solutions for everything from glyconanoparticle development to final drug release studies. Specific services include the following:
Alzheimer's Disease
Alzheimer's disease is a neurological disorder that causes behavioral and cognitive impairments. Traditional therapeutic drugs are limited by their poor solubility and low bioavailability. We design, produce, and characterize glyconanoparticles and analyze their potential to deliver relevant drugs to the brain.
PD
Current PD therapies mainly target dopamine or its precursor (levodopa). These therapies are hampered by their blood-brain barrier and poor bioavailability. For this reason, we develop multiple glyconanoparticles for targeted delivery of multiple drugs.
Below is the general flow of our services:
Glyconanoparticle design
We develop glyconanoparticles for many types of neurological drugs. The design of the nanoparticles involves controlling the particle size, surface area, and surface properties to carry the necessary amount of drug. Ultimately the glyconanoparticle exerts the desired pharmacological activity by releasing the drug to achieve site-specific therapeutic effects.
Development of Glyconanoparticles
We are skilled in various methods of preparing glyconanoparticles. After understanding the specific glyconanoparticle requirements, we select appropriate methods to develop glyconanoparticles including hydrophobic effects, click chemistry, nucleophilic substitution, coulombic interactions, etc. The glyconanoparticles are modified to improve their stability. The final prepared glyconanoparticles are stable, biodegradable, and provide a sustainable drug release profile. In addition to this, Glycol Nanohydrogel is also developed by us for targeted drug delivery.
Characterization and Preclinical Studies of Glyconanoparticles
We combine various experimental methods to analyze the physical and chemical properties of glyconanoparticles, including particle size, surface charge, chemical composition and morphology, and interactions. In addition, we also analyze the effect of pH, drug concentration, etc., on the embedding efficiency, and combine adsorption tests and drug release tests to analyze the safety and efficacy of glyconanoparticles for drug delivery.
Our services include but are not limited to the following drugs:
| Donepezil | Tacrine | Selegiline |
| Vinpocetine | Apomorphine | Rotigotine |
| Rivastigmine | Ginkgo Biloba Extract | Ropinirole |
| Galantamine | Bromocriptine | Coenzyme Q10 |
| Folic Acid | Levodopa | l-Dopa |
| Selegiline | Pramipexole | Dopamine |
Workflow
We have a team of professionals with rich experience in Glyconanoparticle Formulation to provide a neurological drug-loaded glyconanoparticle formulation service to our clients. Our researchers use core technologies to develop high-quality glyconanoparticles for optimal drug loading without compromising drug stability, ensuring targeted delivery and minimizing off-target effects.

Applications
- The glyconanoparticle is loaded with neurological drugs to enable drug targeting and to improve therapeutic efficacy in the treatment of neurological diseases such as PD and Alzheimer's disease.
- The glyconanoparticle is used to deliver neurological drugs and has an important role in the development of co-administration strategies.
- Neurological drug-loaded glyconanoparticle formulation plays an important role in the development of personalized therapeutic strategies for neurological diseases.
Advantages
- We have extensive expertise in nanotechnology and pharmaceutical formulation and specialize in developing tailored experimental protocols for each specific research goal.
- We conduct detailed characterization and comprehensive preclinical studies of glyconanoparticles to meet specific drug delivery requirements.
- Rigorous testing and evaluation ensure the safety and efficacy of glyconanoparticles in drug delivery applications.
Publication Data
Technology: Self-assembly
Journal: Nanoscale Advances
IF: 4.7
Published: 2022
Results: This paper describes PD, current therapeutic alternatives, and novel polymer nanoparticle drug delivery systems for PD dopamine and levodopa replacement. Drugs currently used for the treatment of PD include dopamine precursor drugs, among others. Nanoparticle drug delivery systems are being used to overcome shortcomings such as poor bioavailability and pharmacokinetic profiles in PD drug therapy. They enable drug molecules to be transported to specific targets in the brain by means of sustainable drug release at their site of action.
Fig.1 A nanopolymer-based drug system. (Alabrahim & Azzazy, 2022)
Frequently Asked Questions
- What types of drugs are glyconanoparticles used to load?
Glyconanoparticles are used to load a wide variety of drugs, including small molecules, peptides, nucleic acids, proteins, etc., in neurological disorders such as Alzheimer's disease and PD. Without compromising drug stability, glyconanoparticles are used for targeted delivery of drugs to specific targets to enhance biocompatibility and improve therapeutic efficacy. - How to get started with neurological drug-loaded glyconanoparticle formulation services?
You can contact our service team through our website or directly by email. We are the first to work with you to discuss specific project requirements, timelines, and any other details needed to initiate experiments.
CD BioGlyco draws on its extensive experience in glyconanoparticle development to provide an integrated and innovative neurological drug-loaded glyconanoparticle formulation service from design and preparation to final preclinical studies. We are committed to innovation and provide extensive support for research into neurological disease therapies. Welcome to contact us if you are interested in this service or have a request.
Reference
- Alabrahim. O.A.A.; Azzazy, H.M.E.S. Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease. Nanoscale advances. 2022, 4(24): 5233-5244.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




